{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:40:51Z","timestamp":1781264451498,"version":"3.54.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","techvir.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Techniques in Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.tvir.2025.101081","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:31:12Z","timestamp":1759541472000},"page":"101081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evolving Strategies in the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Narrative Review of Locoregional and Surgical Therapies"],"prefix":"10.1016","volume":"28","author":[{"given":"Juana Valentina","family":"Barrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Pilar","family":"Bayona Molano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.tvir.2025.101081_bib0083","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.tvir.2025.101081_bib0001","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.tvir.2025.101081_bib0002","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1008285123736","article-title":"Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials","volume":"8","author":"Simonetti","year":"1997","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.tvir.2025.101081_bib0003","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.tvir.2025.101081_bib0004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.tvir.2025.101081_bib0005","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jrr\/rru104","article-title":"The role of radiotherapy in the treatment of hepatocellular carcinoma with portal vein tumor thrombus","volume":"56","author":"Yeh","year":"2015","journal-title":"J Radiat Res"},{"issue":"5","key":"10.1016\/j.tvir.2025.101081_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063864","article-title":"Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and\/or inferior vena cava tumor thrombosis","volume":"8","author":"Xi","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.tvir.2025.101081_bib0007","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00000658-200103000-00012","article-title":"Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus","volume":"233","author":"Minagawa","year":"2001","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.tvir.2025.101081_bib0008","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1186\/s12885-017-3895-z","article-title":"Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.tvir.2025.101081_bib0009","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jhep.2023.03.032","article-title":"Are patients with hepatocellular carcinoma and portal vein tumour thrombosis candidates for liver transplantation?","volume":"78","author":"Soin","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.tvir.2025.101081_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12885-020-07708-1","article-title":"Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study","volume":"21","author":"Lim","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.tvir.2025.101081_bib0011","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2214\/ajr.168.3.9057522","article-title":"Dodd GD 3rd, Baron RL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics","volume":"168","author":"Tublin","year":"1997","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.tvir.2025.101081_bib0012","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular Liver disorders, portal vein thrombosis, and procedural bleeding in patients with Liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.tvir.2025.101081_bib0013","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12013-014-9817-7","article-title":"The diagnostic value of tumor biomarkers for detecting hepatocellular carcinoma accompanied by portal vein tumor thrombosis","volume":"69","author":"Liu","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.tvir.2025.101081_bib0014","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0049-3848(03)00183-X","article-title":"Plasma levels of d-dimer and soluble fibrin polymer in patients with hepatocellular carcinoma: a possible predictor of tumor thrombosis","volume":"109","author":"Kim","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.tvir.2025.101081_bib0015","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s00268-012-1866-8","article-title":"Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma","volume":"37","author":"Zhou","year":"2013","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.tvir.2025.101081_bib0016","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00534-010-0314-0","article-title":"A new classification for hepatocellular carcinoma with portal vein tumor thrombus","volume":"18","author":"Shi","year":"2011","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"32","key":"10.1016\/j.tvir.2025.101081_bib0017","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.3748\/wjg.v22.i32.7289","article-title":"Management of hepatocellular carcinoma with portal vein tumor thrombosis: review and update at 2016","volume":"22","author":"Chan","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"20","key":"10.1016\/j.tvir.2025.101081_bib0018","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"10126","key":"10.1016\/j.tvir.2025.101081_bib0019","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"10064","key":"10.1016\/j.tvir.2025.101081_bib0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.tvir.2025.101081_bib0021","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.tvir.2025.101081_bib0022","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.tvir.2025.101081_bib0024","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.tvir.2025.101081_bib0025","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.annonc.2023.12.008","article-title":"Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040","volume":"35","author":"El-Khoueiry","year":"2024","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.tvir.2025.101081_bib0026","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.tvir.2025.101081_bib0027","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1158\/1078-0432.CCR-23-2124","article-title":"FDA approval summary: tremelimumab in combination with Durvalumab for the treatment of patients with unresectable hepatocellular carcinoma","volume":"30","author":"Patel","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10408","key":"10.1016\/j.tvir.2025.101081_bib0023","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.tvir.2025.101081_bib0028","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10064","key":"10.1016\/j.tvir.2025.101081_bib0029","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on Sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.tvir.2025.101081_bib0030","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs Sorafenib alone in hepatocellular carcinoma: the NRG Oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tvir.2025.101081_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1010726","article-title":"Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: a meta-analysis","volume":"12","author":"Luo","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.tvir.2025.101081_bib0033","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/(SICI)1097-0142(19970601)79:11<2087::AID-CNCR5>3.0.CO;2-M","article-title":"The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study","volume":"11","author":"Lee","year":"1997","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.tvir.2025.101081_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4930","article-title":"Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis","volume":"6","author":"Sonbol","year":"2020","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.tvir.2025.101081_bib0034","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00330-016-4511-3","article-title":"Transarterial chemoembolization of hepatocellular carcinoma with segmental portal vein tumour thrombus","volume":"27","author":"Choi","year":"2017","journal-title":"Eur Radiol"},{"issue":"4","key":"10.1016\/j.tvir.2025.101081_bib0035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000523997","article-title":"Guidelines for diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus in China (2021 Edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Liver Cancer"},{"issue":"9","key":"10.1016\/j.tvir.2025.101081_bib0036","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1097\/JS9.0000000000001691","article-title":"Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a randomized clinical trial","volume":"110","author":"Zhou","year":"2024","journal-title":"Int J Surg"},{"key":"10.1016\/j.tvir.2025.101081_bib0037","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-230X-13-60","article-title":"Transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis","volume":"13","author":"Xue","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.tvir.2025.101081_bib0038","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1245\/s10434-010-1321-8","article-title":"unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a prospective comparative study","volume":"18","author":"Luo","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.tvir.2025.101081_bib0039","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1148\/radiol.10101058","article-title":"Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival","volume":"258","author":"Chung","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.tvir.2025.101081_bib0040","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1440-1746.2008.05728.x","article-title":"Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion","volume":"24","author":"Kim","year":"2009","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.tvir.2025.101081_bib0041","first-page":"2847","article-title":"Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi","volume":"12","author":"Zhou","year":"2011","journal-title":"Asian Pac J Cancer Prev"},{"issue":"8","key":"10.1016\/j.tvir.2025.101081_bib0042","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.hpb.2017.04.016","article-title":"Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis","volume":"19","author":"Silva","year":"2017","journal-title":"HPB (Oxford)"},{"issue":"17","key":"10.1016\/j.tvir.2025.101081_bib0043","doi-asserted-by":"crossref","first-page":"29416","DOI":"10.18632\/oncotarget.15075","article-title":"Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"20","key":"10.1016\/j.tvir.2025.101081_bib0044","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1002\/cncr.33677","article-title":"Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: a prospective randomized study","volume":"127","author":"Ding","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.tvir.2025.101081_bib0045","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/curroncol30010096","article-title":"Efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors for hepatocellular carcinoma patients with Portal vein tumor thrombus: a systematic review and meta-analysis","volume":"30","author":"Deng","year":"2023","journal-title":"Current Oncology"},{"issue":"1","key":"10.1016\/j.tvir.2025.101081_bib0046","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"CHANCE001 Investigators. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.tvir.2025.101081_bib0047","doi-asserted-by":"crossref","unstructured":"Benson AB, D'Angelica MI, Abbott DE. Hepatobiliary cancers, Version 2.2021. JNCCN Journal of the National Comprehensive Cancer Network, 19(5):541-565, 2021. https:\/\/doi.org\/10.6004\/jnccn.2021.0022","DOI":"10.6004\/jnccn.2021.0022"},{"issue":"6","key":"10.1016\/j.tvir.2025.101081_bib0048","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"issue":"Issue 2","key":"10.1016\/j.tvir.2025.101081_bib0049","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jvir.2024.10.034","article-title":"Yttrium-90 radioembolization has become the most utilized bridging treatment for liver transplant candidates in the United States","volume":"36","author":"Salem","year":"2025","journal-title":"J Vasc Intervent Radiol"},{"issue":"4","key":"10.1016\/j.tvir.2025.101081_bib0050","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jhep.2017.12.026","article-title":"Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion","volume":"68","author":"Spreafico","year":"2018","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.tvir.2025.101081_bib0051","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00270-019-02404-5","article-title":"Ablative transarterial radioembolization improves survival in patients with HCC and portal vein tumor thrombus","volume":"43","author":"Cardarelli-Leite","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.tvir.2025.101081_bib0052","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00270-024-03935-2","article-title":"Radioembolization as a spearhead treatment of hepatocellular carcinoma with localized portal vein tumor thrombosis (RESOLVE): protocol for an open-label, multi-center, single-arm trial","volume":"48","author":"Choi","year":"2025","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"10","key":"10.1016\/j.tvir.2025.101081_bib0053","doi-asserted-by":"crossref","first-page":"512","DOI":"10.4329\/wjr.v16.i10.512","article-title":"Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma","volume":"16","author":"Hao","year":"2024","journal-title":"World J Radiol"},{"issue":"13","key":"10.1016\/j.tvir.2025.101081_bib0054","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/cncr.29275","article-title":"Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis","volume":"121","author":"Kokabi","year":"2015","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.tvir.2025.101081_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154986","article-title":"Radioembolization is a safe and effective treatment for hepatocellular carcinoma with Portal vein thrombosis: a propensity score analysis","volume":"11","author":"Cho","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.tvir.2025.101081_bib0056","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.tvir.2025.101081_bib0057","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus Sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.tvir.2025.101081_bib0058","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3348\/kjr.2018.0496","article-title":"Comparison of radioembolization and Sorafenib for the treatment of hepatocellular carcinoma with Portal vein tumor thrombosis: a systematic review and meta-analysis of safety and efficacy","volume":"20","author":"Kim","year":"2019","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.tvir.2025.101081_bib0059","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","article-title":"Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma","volume":"71","author":"Ricke","year":"2019","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.tvir.2025.101081_bib0060","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.14309\/ajg.0000000000002467","article-title":"Immunotherapy and transarterial radioembolization combination treatment for advanced hepatocellular carcinoma","volume":"118","author":"Yeo","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.tvir.2025.101081_bib0061","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1158\/1078-0432.CCR-23-0581","article-title":"A phase I\/IIa trial of Yttrium-90 radioembolization in combination with Durvalumab for locally advanced unresectable hepatocellular carcinoma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tvir.2025.101081_bib0062","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.tvir.2025.101081_bib0063","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005457","article-title":"Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study","volume":"10","author":"de la Torre-Al\u00e1ez","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.tvir.2025.101081_bib0064","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/oncolo\/oyad331","article-title":"A pilot study of Pembrolizumab in combination with Y90 radioembolization in subjects with poor prognosis hepatocellular carcinoma","volume":"29","author":"Yu","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.tvir.2025.101081_bib0065","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0041-1734367","article-title":"Transarterial chemoembolization in unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a tertiary Care Center experience","volume":"31","author":"Patidar","year":"2021","journal-title":"Indian J Radiol Imaging"},{"issue":"7","key":"10.1016\/j.tvir.2025.101081_bib0066","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2967\/jnumed.117.199752","article-title":"90Y Radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort","volume":"59","author":"Abouchaleh","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.tvir.2025.101081_bib0067","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1097\/TP.0000000000003162","article-title":"Experience with LDLT in patients with hepatocellular carcinoma and portal vein tumor thrombosis postdownstaging","volume":"104","author":"Soin","year":"2020","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.tvir.2025.101081_bib0069","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jhep.2016.05.044","article-title":"Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion","volume":"65","author":"Kokudo","year":"2016","journal-title":"J Hepatol"},{"issue":"17","key":"10.1016\/j.tvir.2025.101081_bib0070","first-page":"8119","article-title":"Recent advances in treatment strategies for hepatocellular carcinoma with portal vein cancer thrombus","volume":"27","author":"Tan","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.tvir.2025.101081_bib0068","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/SLA.0000000000000236","article-title":"Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma","volume":"260","author":"Zhong","year":"2014","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.tvir.2025.101081_bib0071","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1186\/s12885-017-3895-z","article-title":"Survival benefit of hepatic resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.tvir.2025.101081_bib0072","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/hep.30490","article-title":"An Eastern Hepatobiliary Surgery Hospital\/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study","volume":"69","author":"Zhang","year":"2019","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.tvir.2025.101081_bib0073","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.21037\/atm-21-3937","article-title":"Comparison of treatments for hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and network meta-analysis","volume":"9","author":"Luo","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.tvir.2025.101081_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijsu.2022.106753","article-title":"Efficacy and feasibility of surgery and external radiotherapy for hepatocellular carcinoma with portal invasion: a meta-analysis","volume":"104","author":"Lee","year":"2022","journal-title":"Int J Surg"},{"issue":"18","key":"10.1016\/j.tvir.2025.101081_bib0075","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.21037\/atm-21-3937","article-title":"Comparison of treatments for hepatocellular carcinoma patients with portal vein thrombosis: a systematic review and network meta-analysis","volume":"9","author":"Luo","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.tvir.2025.101081_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104083","article-title":"Survival benefit of perioperative locoregional adjuvant treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and bayesian network meta-analysis","volume":"189","author":"Sun","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.tvir.2025.101081_bib0077","first-page":"889","article-title":"Which is the best combination of surgery for hepatocellular carcinoma with hepatic\/portal vein thrombosis in China: a network meta-analysis of randomized controlled trials","volume":"26","author":"Wu","year":"2021","journal-title":"J BUON"},{"key":"10.1016\/j.tvir.2025.101081_bib0078","doi-asserted-by":"crossref","unstructured":"Abdelhamed W., Shousha H., El-Kassas M. Portal vein tumor thrombosis in hepatocellular carcinoma patients: is it the end?, Liver Res,8, Issue 3,2024, 141-151, ISSN 2542-5684, https:\/\/doi.org\/10.1016\/j.livres.2024.09.002.","DOI":"10.1016\/j.livres.2024.09.002"},{"issue":"1","key":"10.1016\/j.tvir.2025.101081_bib0079","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.tvir.2025.101081_bib0080","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/gutjnl-2014-308513","article-title":"Liver transplantation for hepatocellular carcinoma beyond the Milan criteria","volume":"65","author":"Xu","year":"2016","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.tvir.2025.101081_bib0082","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.jhep.2023.10.031","article-title":"Patients with hepatocellular carcinoma and portal vein tumour thrombosis after successful downstaging may be candidates for liver transplantation: a meta-analysis","volume":"80","author":"Liu","year":"2024","journal-title":"J Hepatol"}],"container-title":["Techniques in Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089251625000630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089251625000630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T01:17:15Z","timestamp":1763601435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089251625000630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1089251625000630"],"URL":"https:\/\/doi.org\/10.1016\/j.tvir.2025.101081","relation":{},"ISSN":["1089-2516"],"issn-type":[{"value":"1089-2516","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving Strategies in the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Narrative Review of Locoregional and Surgical Therapies","name":"articletitle","label":"Article Title"},{"value":"Techniques in Vascular and Interventional Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvir.2025.101081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101081"}}